Romidepsin and afatinib abrogate JAK-STAT signaling and elicit synergistic antitumor effects in cutaneous T-cell lymphoma
Cutaneous T-cell lymphomas (CTCL) are mature lymphoid neoplasias resulting from the malignant transformation of skin-resident T cells. A distinctive clinical feature of CTCL is their sensitivity to treatment with histone deacetylase (HDAC) inhibitors. However, responses to HDAC inhibitor therapy are universally transient and non-curative, highlighting the need for effective and durable drug combinations. Here we demonstrate that the combination of romidepsin, a selective class I HDAC inhibitor, with afatinib, an epidermal growth factor receptor (EGFR) family inhibitor, induces strongly synergistic antitumor effects in CTCL...
Source: Journal of Investigative Dermatology - January 12, 2024 Category: Dermatology Authors: Bobby B. Shih, Cindy Ma, Jose R. Cortes, Clara Reglero, Hannah Miller, S. Aidan Quinn, Robert Albero, Anouchka P. Laurent, Adam Mackey, Adolfo A. Ferrando, Larisa Geskin, Teresa Palomero Tags: Original Article Source Type: research
Romidepsin and Afatinib Abrogate Jak –Signal Transducer and Activator of Transcription Signaling and Elicit Synergistic Antitumor Effects in Cutaneous T-Cell Lymphoma
In this study, we demonstrate that the combination of romidepsin, a selective class I histone deacetylase inhibitor, with afatinib, an EGFR family inhibitor, induces strongly synergistic antitumor effects in cutaneous T-cell lymphoma models in vitro and in vivo through abrogation of Jak–signal transducer and activator of transcription signaling. (Source: Journal of Investigative Dermatology)
Source: Journal of Investigative Dermatology - January 12, 2024 Category: Dermatology Authors: Bobby B. Shih, Cindy Ma, Jose R. Cortes, Clara Reglero, Hannah Miller, S. Aidan Quinn, Robert Albero, Anouchka P. Laurent, Adam Mackey, Adolfo A. Ferrando, Larisa Geskin, Teresa Palomero Tags: Original Article Source Type: research
Effectiveness and tolerability of chlormethine gel for the management of mycosis fungoides: a multicenter real-life evaluation
ConclusionsOur observations support the use of CL gel in patients with early- and advanced-stage MF, making it a valuable treatment option. (Source: Frontiers in Oncology)
Source: Frontiers in Oncology - January 4, 2024 Category: Cancer & Oncology Source Type: research
Racial disparities in Mycosis Fungoides/S ézary Syndrome – A Single-center observational study of 292 patients.
In this study, we aim to characterize differences between AA/black and white patients with MF/SS. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 3, 2024 Category: Hematology Authors: Ashley R. Gandham, Shamir Geller, Stephen W. Dusza, Thomas S. Kupper, Patricia. L. Myskowski Tags: Original Study Source Type: research
Racial Disparities in Mycosis Fungoides/S ézary Syndrome–A Single-Center Observational Study of 292 Patients
We report worse survival in black patients compared to white patients with different survival risk for hypopigmentation, erythroderma and ulceration between the races. The underlying mechanisms require further investigation and may have impact on treatment strategies in these groups. (Source: Clinical Lymphoma, Myeloma and Leukemia)
Source: Clinical Lymphoma, Myeloma and Leukemia - January 3, 2024 Category: Hematology Authors: Ashley R. Gandham, Shamir Geller, Stephen W. Dusza, Thomas S. Kupper, Patricia. L. Myskowski Tags: Original Study Source Type: research
